Partners | Companies

Anaxomics Biotech SL (Anaxomics)

Anaxomics Biotech SL (Anaxomics)

Anaxomics offers expert consulting services based on a unique combination of cutting-edge Systems Biology and Artificial Intelligence (Machine Learning) and our expertise in the fields of drug discovery, pre-clinical and clinical development.

Our proprietary technology, TPMS integrates both molecular and clinical information, what confers it a translational capability and makes it ideal to explore clinical outcomes in preclinical and early stage clinical projects (e.g. drug repositioning, molecular mechanism identification, biological analysis of high-throughput data, improving in- and out- licensing opportunities, precision medicine,...) as well as to molecularly explain observations at more advanced clinical stages (e.g. biomarker discovery, responders vs. non responders, molecular interpretation of failed clinical trials, clinical trial design...). We are experts on providing our customers with scientific rationales for their drugs or pathophysiological or clinical observations.

During our 10 years of life, Anaxomics has provided Drug Repositioning, Efficacy and Safety Prediction Analysis, Mechanism of Action Identification, Biomarker Discovery... among other services, to biotech and pharmaceutical companies around the globe, with 200+ customer-oriented projects performed and having participated as partners in 10+ European projects (FP7, H2020).


Bioinformatics services


Main Projects

Our main focus is working as service providers for pharma, biotech, and (basic/clinic) researcher clients. We have performed 300+ projects for clients, and we are also very active in European projects, having performed 6 FP7 projects and being a partner of several H2020 projects. Amongst the collaborative projects currently active we are partners of:

  • LIVERHOPE: LIVERHOPE brings together 16 partners from 7 different European countries with industrial and academic background. The primary objective of the project is to improve the quality of the life and survival of the patients by the efficacy of treatment with the combination of rifaximin, an antibiotic that modulates the intestinal microbiome, and statins in patients with advanced cirrhosis and the search for biomarkers of the disease.
  • SyStemAge: The regenerative power of a living organism is linked to the potential of its stem cells to replace the corresponding damaged tissue. Therefore organisms are as old as their stem cells. We intend to apply integrative systems biology approaches to characterize the molecular players, genes and pathways that are associated with physiological processes of ageing and two age-related disorders, myelodysplastic syndromes (MDS) and B-cell chronic lymphocytic leukemia (B-CLL). We will use the resulting models of ageing to develop novel molecular targeted strategies to treat age-related diseases.
  • CombiMS: The therapeutic challenge of complex diseases requires the use of combination therapies to target the distinct mechanisms and pathways involved. Such complex diseases will benefit from the design of computational models adopting a systems perspective to integrate the knowledge generated by 'omics technologies and clinical data. Multiple Sclerosis is a prototypic debilitating complex disease in which an autoimmune attack is launched against the brain. The mechanistic modelling will be extended to the different levels of the response to therapy by analysing biological networks integrating gene and protein networks, with drugs, their effects and side-effects.